Submissions for variant NM_004369.4(COL6A3):c.6310-2A>G

dbSNP: rs1559225993

Total submissions: 3

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV000692116	SCV000819924	pathogenic	Bethlem myopathy 1A	2021-04-04	criteria provided, single submitter	clinical testing	For these reasons, this variant has been classified as Pathogenic. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in COL6A3 are known to be pathogenic (PMID: 20976770). In addition, donor and acceptor splice site variants in COL6A3 that result in in-frame exon skipping have also been reported to cause autosomal dominant COL6A3-related conditions (PMID: 18366090). This variant has been observed in individual(s) with clinical features of autosomal dominant type VI collagenopathy (PMID: 23572247, Invitae). Disruption of this splice site has been observed to be de novo in an individual with autosomal dominant Ullrich congenital muscular dystrophy. However, this individual also carried a different splice acceptor on the same chromosome (in cis) that was also de novo (PMID: 31044083). ClinVar contains an entry for this variant (Variation ID: 571080). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 18 of the COL6A3 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product.
Revvity Omics, Revvity	RCV001784315	SCV002023346	likely pathogenic	not provided	2019-03-29	criteria provided, single submitter	clinical testing
Neuberg Centre For Genomic Medicine, NCGM	RCV003338733	SCV004048575	pathogenic	Ullrich congenital muscular dystrophy 1A		criteria provided, single submitter	clinical testing	The splice acceptor variant c.6310-2A>G in COL6A3 gene has been previously observed in individual(s) with clinical features of autosomal dominant type VI collagenopathy (Yonekawa et al. 2013). This sequence change affects an acceptor splice site in intron 18 of the COL6A3 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. Disruption of this splice site has been observed to be de novo in an individual with autosomal dominant Ullrich congenital muscular dystrophy. However, this individual also carried a different splice acceptor on the same chromosome (in cis) that was also de novo (Shimomura et al. 2019). Donor and acceptor splice site variants typically lead to a loss of protein function (Baralle et al. 2005), and lossof-function variants in COL6A3 are known to be pathogenic (Briñas et al. 2010). In addition, donor and acceptor splice site variants in COL6A3 that result in inframe exon skipping have also been reported to cause autosomal dominant COL6A3-related conditions (Lampe et al. 2008). This variant has been reported to the ClinVar database with conflicting interpretations of pathogenicity as Pathogenic/Likely Pathogenic. The variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. The nucleotide change in COL6A3 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.